- Home
- SORA vs INKT Comparison
SORA vs INKT Comparison
Compare SORA & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SORA | INKT |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | Hong Kong | United States |
| Employees | 7 | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.5M | 53.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SORA | INKT |
|---|---|---|
| Price | $2.09 | $11.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 7.6K | ★ 188.2K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $6.66 |
| 52 Week High | $10.27 | $76.00 |
Technical Indicators
Market Signals| Indicator | SORA | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 48.31 | 56.21 |
| Support Level | $1.76 | $10.94 |
| Resistance Level | $2.15 | $11.65 |
| Average True Range (ATR) | 0.12 | 0.96 |
| MACD | 0.02 | 0.26 |
| Stochastic Oscillator | 46.65 | 72.54 |
Price Performance
Historical ComparisonAbout SORA Top Win International Limited Ordinary Shares
AsiaStrategy is a wholesaler engaged in trading, distribution, and retail of luxury watches of international brands. The Group sources its luxury watches from Europe, Singapore, Japan, and Hong Kong, then sells the goods to retail sellers and other distributors in the watch industry.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.